AR095352A1 - Compuesto y composición farmacéuticamente aceptable, útil para tratar una afección o trastorno tal como una enfermedad de proliferación celular, diabetes, inflamación, enfermedad cardíaca, ictus, epilepsia, depresión, enfermedad inmunológica e infección vírica o fúngica o patología neurodegenerativa - Google Patents

Compuesto y composición farmacéuticamente aceptable, útil para tratar una afección o trastorno tal como una enfermedad de proliferación celular, diabetes, inflamación, enfermedad cardíaca, ictus, epilepsia, depresión, enfermedad inmunológica e infección vírica o fúngica o patología neurodegenerativa

Info

Publication number
AR095352A1
AR095352A1 ARP140101056A ARP140101056A AR095352A1 AR 095352 A1 AR095352 A1 AR 095352A1 AR P140101056 A ARP140101056 A AR P140101056A AR P140101056 A ARP140101056 A AR P140101056A AR 095352 A1 AR095352 A1 AR 095352A1
Authority
AR
Argentina
Prior art keywords
disease
immune
composition
pharmaceutically acceptable
patheological
Prior art date
Application number
ARP140101056A
Other languages
English (en)
Inventor
Dominguez Celia
Muoz Ignacio
Beaumont Vahri
Beconi Maria
W Burli Roland
F Haughan Alan
A Luckhurst Christopher
Wall Michael
Raphy Gilles
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of AR095352A1 publication Critical patent/AR095352A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1) o alguna de sus sales farmacéuticamente aceptable, caracterizado porque R es pirimidina sustituida con 1 ó 2 grupos seleccionados independientemente de halo, alquilo C₁₋₄, y haloalquilo C₁₋₄; cada R¹ se selecciona independientemente de halo, alquilo C₁₋₄, y haloalquilo C₁₋₄; y m es 1; 2 ó 3.
ARP140101056A 2013-03-14 2014-03-14 Compuesto y composición farmacéuticamente aceptable, útil para tratar una afección o trastorno tal como una enfermedad de proliferación celular, diabetes, inflamación, enfermedad cardíaca, ictus, epilepsia, depresión, enfermedad inmunológica e infección vírica o fúngica o patología neurodegenerativa AR095352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785759P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095352A1 true AR095352A1 (es) 2015-10-07

Family

ID=51625122

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101056A AR095352A1 (es) 2013-03-14 2014-03-14 Compuesto y composición farmacéuticamente aceptable, útil para tratar una afección o trastorno tal como una enfermedad de proliferación celular, diabetes, inflamación, enfermedad cardíaca, ictus, epilepsia, depresión, enfermedad inmunológica e infección vírica o fúngica o patología neurodegenerativa

Country Status (7)

Country Link
US (2) US9562021B2 (es)
EP (1) EP2968232B1 (es)
JP (1) JP6363164B2 (es)
AR (1) AR095352A1 (es)
HK (1) HK1220461A1 (es)
TW (1) TW201514153A (es)
WO (1) WO2014159210A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562021B2 (en) * 2013-03-14 2017-02-07 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2014159224A1 (en) 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP2968207A4 (en) 2013-03-14 2016-09-28 Chdi Foundation Inc HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS
JP6600319B2 (ja) 2014-06-02 2019-10-30 シーエイチディーアイ ファウンデーション，インコーポレーテッド ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US10555984B2 (en) * 2017-04-21 2020-02-11 Tci Co., Ltd. Method for increasing expression of PDPRD gene by using peanut skin extract

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074132A1 (en) * 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008101186A1 (en) * 2007-02-15 2008-08-21 The J. David Gladstone Institutes Inhibitors for hdac8
TWI539947B (zh) 2007-04-09 2016-07-01 米希爾金尼公司 組蛋白去乙醯基酶之抑制劑
WO2009055917A1 (en) * 2007-11-02 2009-05-07 Methylgene Inc. Inhibitors of histone deacetylase
CN101863901B (zh) * 2010-06-29 2012-12-05 天津药物研究院 2-(取代苯基)-2-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5(4H)-基)-N-取代-乙酰胺、其制备方法和用途
TW201245115A (en) 2011-01-24 2012-11-16 Chdi Foundation Inc Histone deacetylase inhibitors and compositions and methods of use thereof
TW201408628A (zh) 2012-07-16 2014-03-01 Chdi Foundation Inc 組蛋白去乙醯酶抑制劑及組成物，暨其使用之方法
WO2014159214A1 (en) 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
US9562021B2 (en) * 2013-03-14 2017-02-07 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2014159224A1 (en) 2013-03-14 2014-10-02 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EP2968207A4 (en) 2013-03-14 2016-09-28 Chdi Foundation Inc HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS
JP6600319B2 (ja) 2014-06-02 2019-10-30 シーエイチディーアイ ファウンデーション，インコーポレーテッド ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法

Also Published As

Publication number Publication date
WO2014159210A1 (en) 2014-10-02
JP2016512512A (ja) 2016-04-28
EP2968232A1 (en) 2016-01-20
TW201514153A (zh) 2015-04-16
EP2968232B1 (en) 2018-12-05
JP6363164B2 (ja) 2018-07-25
EP2968232A4 (en) 2016-08-03
US20160024019A1 (en) 2016-01-28
US20170224684A1 (en) 2017-08-10
US9562021B2 (en) 2017-02-07
HK1220461A1 (zh) 2017-05-05
US10105363B2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
AR095352A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar una afección o trastorno tal como una enfermedad de proliferación celular, diabetes, inflamación, enfermedad cardíaca, ictus, epilepsia, depresión, enfermedad inmunológica e infección vírica o fúngica o patología neurodegenerativa
ECSP18048718A (es) Imidazolilimidazoles condensados como compuestos antivirales
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CL2016000918A1 (es) Compuestos derivados de pirimidin amidas con actividad inhibidora del factor de crecimiento fgfr (fgfr4 y fgf19); composición farmacéutica que los comprende y uso en el tratamiento del carcinoma hepatocelular.
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
EA201890450A1 (ru) Циклические динуклеотидные соединения в качестве агонистов sting
CR20150370A (es) Compuestos antivirales
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
CR20140464A (es) Compuestos de heterociclilo
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
EA201591527A1 (ru) Новые производные пиридина
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
ECSP14013251A (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO7350652A2 (es) Piridina-2-amidas útiles como agonistas de cb2
MA40076A (fr) Inhibiteurs de syk
MX2014013660A (es) Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b.
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
ECSP14030779A (es) Inhibidores del nampt
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
EA201690844A1 (ru) Ингибиторы gsk-3
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201591567A1 (ru) Новые производные пиридина
EA201591976A1 (ru) Производные пурина в качестве агонистов каннабиноидного рецептора cb2

Legal Events

Date Code Title Description
FB Suspension of granting procedure